Hologic Inc.
Hologic, Inc. Refinances Term Loan and Revolving Credit Facility
Summary
On July 15, 2025, Hologic, Inc. refinanced its term loan and revolving credit facility by entering into Refinancing Amendment No. 4 to its Amended and Restated Credit and Guaranty Agreement. The refinancing resulted in a $1.169 billion secured term loan with a maturity date of July 15, 2030, and a $1.250 billion secured revolving credit facility with a maturity date of July 15, 2030. The refinancing provides additional flexibility for the Company and its subsidiaries under certain covenants. All defined terms used in this Current Report on Form 8-K that are not otherwise defined herein have the meanings ascribed to such terms in the Amended Credit Agreement.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement